Study of Azelaprag and Tirzepatide for Older Adults with Obesity Terminated
Background
Obesity is a growing global health concern, particularly in older adults, often requiring effective pharmacological interventions. Tirzepatide is a highly effective treatment, but there's a continuous search for synergistic therapies to enhance weight loss and improve safety profiles. This study aimed to evaluate the efficacy and safety of adding oral azelaprag to once-weekly tirzepatide in participants aged 55 and over with obesity.
Results
Due to the premature termination of the STRIDES study (NCT06515418), no efficacy or safety data were collected or analyzed. Therefore, there are no results regarding the potential benefits or adverse effects of combining oral azelaprag with tirzepatide in the target population. The study's termination means no conclusions can be drawn about whether this combination therapy could offer enhanced weight management or improved safety compared to tirzepatide alone. > The study was terminated, and no findings or data were reported.
Why It Matters
The termination of this Phase 2 study means a potential avenue for enhanced obesity treatment in older adults remains unexplored. While tirzepatide is highly effective, combination therapies are often sought to improve outcomes or reduce side effects, and azelaprag was hypothesized to offer such benefits. Without data from this trial, the potential synergy of azelaprag with tirzepatide for weight management in older adults is unknown. Future research would be needed to investigate this combination, potentially through a new trial design or different patient population.